OPRK1 and major depressive disorder: Nα-benzylation of a cyclic DYN A-(1-11) analog resulted in the discovery of a highly selective KOR antagonist with desirable therapeutic potentials such as systemic activity, proper duration of action, and the BBB penetration in the treatment of diseases such as depression, anxiety, and drug abuse [18,182].